Troy Wilson

Troy Wilson is a highly-successful, serial entrepreneur. His passion is to build exceptional companies that create significant value for employees, investors, and most importantly, patients. He is one of the co-founders and has served as a member of the board of directors since November 2012. Dr. Wilson has served as President and Chief Executive Officer of Kura Oncology, Inc., a public biopharmaceutical company, since August 2014 and as President and CEO of Wellspring Biosciences LLC, a private biopharmaceutical company, and its parent company Araxes Pharma LLC until March 2019.

Dr. Wilson served as the President and Chief Executive Officer and a member of the board of directors of Intellikine, Inc., a private biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceuticals. He has also been a member of the board of directors of Kura Oncology since August 2014, a member of the board of directors of Puma Biotechnology, Inc., a public biopharmaceutical company, since October 2013, and the sole managing member of Araxes Pharma LLC since May 2012, and Executive Chairman of the board of managers of Wellspring Biosciences since July 2012. He holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.